Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKG 120

Next Previous
Drug Profile

AKG 120

Alternative Names: AKG-120; Ls-AKG38

Latest Information Update: 22 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AKAGERA Medicines
  • Developer AKAGERA Medicines; Vanderbilt University School of Medicine
  • Class Antibacterials; Antituberculars; Carbamates; Fluorobenzenes; Oxazolidinones; Small molecules; Spiro compounds
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial endocarditis; Osteomyelitis

Most Recent Events

  • 22 Jul 2025 Preclinical trials in Osteomyelitis in USA (unspecified route) (Akagera Medicines pipeline, July 2025)
  • 08 Jul 2025 Akagera Medicines has patent pending for AKG 120 in Europe, Japan, Africa, Australia, Brazil, Canada, China, India, South Korea, Mexico, New Zealand, Hong Kong, Israel and other countries (AKAGERA Medicines website, July 2025)
  • 08 Jul 2025 Preclinical trials in Bacterial endocarditis in USA (unspecified route) (Akagera Medicines pipeline, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top